Literature DB >> 7076404

Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes.

F A Stern, L Z Bito.   

Abstract

It is generally accepted that exogenous or endogenous prostaglandins (PGs) can give rise to acute increases in intraocular pressure (IOP) and to the development of flare and other signs of uveitis. It was recently shown, however, that low doses of PGE2 and/or PGF2 alpha topically applied to rabbit or owl monkey eyes significantly reduce IOP. The present experiments show that topical application of 10 to 500 micrograms of PGE2 also causes a highly significant IOP reduction in cat eyes lasting up to 48 hr with little or no development of flare or miosis, whereas similar application of PGF2 alpha causes, in addition to an IOP reduction, the development of profound pupillary constriction. Topical application of either PGF2 alpha or PGE2 to the eyes of rhesus monkeys also causes significant dose-dependent reduction in IOP. The hypotensive response in the rhesus monkey is not associated with detectable flare or consistent pupillary constriction, although at higher PG doses, hypotension tends to be preceded in both species by a brief (15 to 30 min) hypertensive phase. It is concluded that the eyes of different species show different patterns of IOP, miotic, and flare responses to topically applied PGs, the only consistent effect being a reduction in IOP. In some species, most notably in primates, a reduction in IOP is the predominant effect of PGs. Thus, PGs or their analogues may provide a new approach to the clinical control of IOP and the treatment of glaucoma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7076404

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  15 in total

1.  Ocular neovascularization. Experimental animal model and studies on angiogenic factor(s).

Authors:  S S Hayreh; G F Lata
Journal:  Int Ophthalmol       Date:  1986-05       Impact factor: 2.031

2.  Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma.

Authors:  J Villumsen; A Alm; M Söderström
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

3.  Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats.

Authors:  Jessica E McDonald; Julie A Kiland; Paul L Kaufman; Ellison Bentley; N Matthew Ellinwood; Gillian J McLellan
Journal:  Vet Ophthalmol       Date:  2015-07-16       Impact factor: 1.644

Review 4.  Corticosteroids and glaucoma risk.

Authors:  R C Tripathi; S K Parapuram; B J Tripathi; Y Zhong; K V Chalam
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

5.  Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes.

Authors:  J Villumsen; A Alm
Journal:  Br J Ophthalmol       Date:  1989-06       Impact factor: 4.638

Review 6.  Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma.

Authors:  Peter G Klimko; Najam A Sharif
Journal:  Br J Pharmacol       Date:  2018-05-17       Impact factor: 8.739

7.  The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1993-02       Impact factor: 4.638

8.  The different contributions of prostaglandins (E1, E2, F2 alpha, D2) to the tone and neurogenic response of bovine iris sphincter muscle.

Authors:  R Suzuki; H Yoshino; S Kobayashi
Journal:  Doc Ophthalmol       Date:  1989-06       Impact factor: 2.379

9.  Effects of prostaglandin D2 and its analogue, BW245C, on intraocular pressure in humans.

Authors:  M Nakajima; Y Goh; I Azuma; O Hayaishi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

10.  Prostaglandin D2 reduces intraocular pressure.

Authors:  Y Goh; M Nakajima; I Azuma; O Hayaishi
Journal:  Br J Ophthalmol       Date:  1988-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.